Michael Artinger, PhD

Michael Artinger, PhD
Michael Artinger, PhD, Executive Vice President and Managing Director VIC Colorado Branch, has spent his career transforming innovation into commercial opportunity. He has worked closely with universities and inventors across the nation to recognize the potential of their discoveries and has deep domain expertise across multiple verticals, including therapeutics, vaccines, medical devices, diagnostics and information technology/software. Dr. Artinger earned his Doctorate degree in Biology focusing on Developmental and Cell Biology, as well as his Baccalaureate degree in Applied Ecology from the University of California at Irvine.
Find me on:

Recent Posts

Inside The VIC Fellows Program

VIC Technology Venture Development’s (www.victech.com) investment model sources promising life science innovation directly from universities across the nation, allocating funding to form startup companies and advance...

Portfolio Diversification in Times of Market Volatility

Privately-Held, Science-Driven Investing in an Uncertain World As of writing this article, it’s mid-July 2020, and the uncertainty around the long-term impact of the COVID-19 pandemic continues to grow. As with any new...

The Emerging Remote Workplace: Digital Best Practices for Investor Groups

As the recent pandemic has made all too clear, organizations need to proactively prepare for the realities of a dispersed workforce, which is especially true for investor groups such as venture capital and private...

White Paper: New Paradigms of Life Science Investing

For decades, only venture capital (VC) firms, and very rarely, angels were able to invest in start-up companies developing life science—therapeutics, medical devices, diagnostics, and related—innovation.  Anyone doing...

White Paper: Accessing Innovation Directly From The Source - The Growing Trend Of Venture Capital Company Formation

Historically, innovative technologies discovered at universities, institutes and national labs have had two primary paths towards commercialization: (1) licensing to a large, pre-existing company; or, (2) licensing to...

FEATURED RESOURCES

News
Solenic Medical Receives FDA Breakthrough Device Designation
White Paper
Portfolio Diversification in Times of Market Volatility
Case Study
The Emerging Remote Workplace: Digital Best Practices for Investor Groups
Reports
VIC 2020 Mid-Year Report
News
VIC Portfolio Companies and Pipeline Technologies with Pandemic Impact
Case Study
Opportunity Assessment: How To Vet So Much Tech
Interview
Behind the Curtain with Biolocity | Guiding Medical Innovations to Market
White Paper
Accessing Innovation Directly from the Source - Growing Trends in Venture Capital Company Formation
News
Zebra Analytix Awarded NIH Funding to Improve Workplace Safety
Interview
VIC Fellow Spotlight: Dr. Natalie Gassman
From The Corner Office
Vixiar: Solving a Big Problem With a Small Device